LCO No. 5674 1 of 2
General Assembly Raised Bill No. 1473
January Session, 2025
LCO No. 5674
Referred to Committee on HUMAN SERVICES
Introduced by:
(HS)
AN ACT REQUIRING MEDICAID COVERAGE FOR FDA -APPROVED
GENE THERAPIES TO TREAT SICKLE CELL DISEASE.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:
Section 1. (NEW) (Effective from passage) (a) The Commissioner of 1
Social Services shall provide Medicaid coverage for gene therapies 2
approved by the federal Food and Drug Administration to treat sickle 3
cell disease. 4
(b) The commissioner shall apply for any federal initiative to increase 5
cost-effective access to the therapies, including, but not limited to, the 6
Cell and Gene Therapy Access Model administered by the Centers for 7
Medicare and Medicaid Services. 8
(c) Not later than January 1, 2026, the commissioner shall file a report, 9
in accordance with the provisions of section 11-4a of the general statutes, 10
with the joint standing committee of the General Assembly having 11
cognizance of matters relating to human services on the (1) efforts to 12
increase cost-effective access to the therapies, (2) number of Medicaid 13
recipients who have received Medicaid coverage for the therapies, (3) 14
cost to the state to provide such therapies, and (4) estimated state 15
Raised Bill No. 1473
LCO No. 5674 2 of 2
appropriations needed to provide such coverage. 16
This act shall take effect as follows and shall amend the following
sections:
Section 1 from passage New section
Statement of Purpose:
To require Medicaid coverage for gene therapies approved by the
federal Food and Drug Administration to treat sickle cell disease.
[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except
that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not
underlined.]